CD4 and AIDS: For example, in the Strategic Timing of Antiretroviral Therapy (START) trial, initiating ART for patients with CD4 >500/μL rather than deferring ART initiation until more advanced disease stages, was shown to reduce risk for a composite endpoint of any serious acquired immunodeficiency syndrome (AIDS)–related event, non-AIDS–related event, or death by 57% (5).